Press releases

All press releases Regulatory

Regulatory press release 2021-04-08

Xspray Pharma announces the results of two bioequivalence studies with adjusted tablet formulation of HyNap-Dasa (ANDA)

Regulatory press release 2021-03-19

Xspray Pharma publishes its annual report for 2020

Press release 2021-03-18

Xspray Pharma aims to submit its improved version of dasatinib for market approval application in second half of 2021

Press release 2021-03-05

Both groups in the two ongoing bioequivalence studies with Xspray Pharma’s product candidate HyNap-Dasa have been dosed

Regulatory press release 2021-02-25

Xspray Pharma publishes Interim report Q4, January – December 2020

Regulatory press release 2021-02-17

Nomination Committee proposes Anders Ekblom as new Chairman of the Board in Xspray Pharma

Regulatory press release 2021-01-29

Number of shares and votes in Xspray Pharma

Regulatory press release 2021-01-26

Warrant holders exercise all warrants within the framework of the incentive program

Regulatory press release 2021-01-22

Xspray Pharmas study with modified formulation of HyNap-Dasa has now started

Regulatory press release 2021-01-14

Xspray Pharma announces results from additional bioequivalence study and provides update regarding upcoming regulatory applications for ANDA and 505(b)(2)

IR contact

Jacob Nyberg, IRO

+46 (0)70 767 08 83

info@xspray.com

Subscribe